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Abstract
Background: Statins decrease cholesteryl ester transfer protein (CETP) levels, which have been positively associated
with hepatic lipid content as well as serum low density lipoproteins-cholesterol (LDL-C) levels. However, the
relationship between the CETP status and statin-induced reductions in LDL-C levels has not yet been elucidated in
detail. We herein examined the influence of the CETP status on the lipid-reducing effects of pitavastatin in
hypercholesterolemic patients with type 2 diabetes mellitus as well as the molecular mechanism underlying
pitavastatin-induced modifications in CETP levels.
Methods: Fifty-three patients were treated with 2 mg of pitavastatin for 3 months. Serum levels of LDL-C, small
dense (sd) LDL-C, and CETP were measured before and after the pitavastatin treatment. The effects of pitavastatin,
T0901317, a specific agonist for liver X receptor (LXR) that reflects hepatic cholesterol contents, and LXR silencing
on CETP mRNA expression in HepG2 cells were also examined by a real-time PCR assay.
Results: The pitavastatin treatment decreased LDL-C, sdLDL-C, and CETP levels by 39, 42, and 23 %, respectively.
Despite the absence of a significant association between CETP and LDL-C levels at baseline, baseline CETP levels
and its percentage change were an independent positive determinant for the changes observed in LDL-C and
sdLDL-C levels. The LXR activation with T0901317 (0.5 μM), an in vitro condition analogous to hepatic cholesterol
accumulation, increased CETP mRNA levels in HepG2 cells by approximately 220 %, while LXR silencing markedly
diminished the increased expression of CETP. Pitavastatin (5 μM) decreased basal CETP mRNA levels by 21 %, and
this was completely reversed by T0901317.
Conclusion: Baseline CETP levels may predict the lipid-reducing effects of pitavastatin. Pitavastatin-induced CETP
reductions may be partially attributed to decreased LXR activity, predictable by the ensuing decline in hepatic
cholesterol synthesis.
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Background
Cholesteryl ester transfer protein (CETP) is a 74-kDa
glycoprotein that is synthesized in liver and adipose tis-
sues and subsequently secreted into the bloodstream [1].
Circulating CETP transfers the cholesterol ester (CE)
from low density lipoproteins (LDL) and high density li-
poproteins (HDL) to very low density lipoproteins
(VLDL) in an equimolecular exchange of triglycerides
(TG) according to their concentrations [2]. Conse-
quently, CETP levels are positively associated with LDL-
C levels [3, 4] and negatively associated with HDL-C
levels [3, 4]. The expression of CETP was recently
reported to be induced by the liver X receptor (LXR)
[5, 6]. As LXR has been identified as a hepatic chol-
esterol sensor [7], serum CETP levels may also be a
surrogate for hepatic lipid content [8].
Small dense (sd) LDL is known to be more atherogenic
than LDL due to its longer half-time, greater penetrance
into arterial walls, and greater susceptibility to oxidative
stress [9]. Several clinical studies demonstrated that
smaller LDL particles were associated with the incidence
of coronary artery disease [10–12]. Dyslipidemia in type
2 diabetes mellitus is characterized by high TG levels,
low HDL-C levels, and high sd LDL –C levels [13]. In
type 2 diabetes mellitus, the production of TG-enriched
VLDL is increased, which readily causes the formation
of TG-rich LDL, a precursor of sd LDL [13, 14]. In the
diabetic condition, CETP also enhances the production
of TG-rich LDL due to its functional properties, leading
to preferable formation of sd LDL [2, 13].
HMG-CoA reductase inhibitors (statins) are widely used
to treat hypercholesterolemia and are known to be useful
for reducing cardiovascular disease events. Previous
studies reported that some statins such as pitavastatin mark-
edly decreased sd LDL-C as well as LDL-C, [15, 16] and
also significantly reduced circulating CETP levels [4, 17].
Considering that CETP plays some role in the production
of atherogenic lipid profiles, its status may modify lipid-
reducing effects of statin treatment. However, this remains
to be clarified. The aim of the present study, therefore, was
to assess not only the influence of the CETP status on the
lipid-reducing effects of pitavastatin in type 2 diabetic
patients with hypercholesterolemia, but also the molecular
mechanism underlying pitavastatin-induced modifications
in the expression of CETP in HepG2 cell lines.
Results
Baseline characteristics
The backgrounds of 53 hypercholesterolemic patients
with type 2 diabetes are shown in Table 1. The mean age
of the patients was 61.1 ± 9.8 years. Twenty-seven pa-
tients were male and 26 were female. The means of body
mass index and HbA1c were 24.8 ± 4.5 kg/m2 and 7.1 ±
0.8 % (NGSP), respectively. Regarding diabetes-related
complications, 5 had diabetic nephropathy (9.4 %). Re-
garding cardiovascular diseases, 23 patients had hyper-
tension (43.4 %), and 4 had coronary artery disease
(7.5 %).
The concurrent administration of drugs for these
subjects is shown in Table 1. As for anti-diabetes agents,
sulfonyl ureas were prescribed for 28 patients, bigua-
nides for 25, α-glucosidase inhibitors for 23, pioglitazone
for 10, and insulin for 5. The anti-lipidemic agent, feno-
fibrate was prescribed for two patients only.
Changes in clinical laboratory data
The changes observed in clinical laboratory data are
shown in Table 2. The pitavastatin treatment significantly
Table 1 The background of the enrolled patients
Characteristics N = 53
Age (years) 61.1 ± 9.8a
Male, n (%) 27 (50.9)b
Body mass index (kg/m2) n = 52 24.8 ± 4.5
Abdominal girth (cm) n = 48 88.7 ± 9.4
Systolic blood pressure (mmHg) n = 52 127.9 ± 12.0
Diastolic blood pressure (mmHg) n = 52 73.3 ± 9.2
HbA1c (%) 7.1 ± 0.8
Complications
Type 2 diabetes, n (%) 53 (100.0)b
diabetic neuropathy, n (%) 10 (18.9)
diabetic nephropathy, n (%) 5 (9.4)
diabetic retinopathy, n (%) 4 (7.5)
Hypertension, n (%) 23 (43.4)
Coronary artery disease, n (%) 4 (7.5)
Cerebral artery disease, n (%) 1 (1.9)
Peripheral artery disease, n (%) 2 (3.8)
Concurrent medications
Anti-diabetic agents
sulfonyl urea 28 (52.8)b
biguanide 25 (47.2)




angiotensin II type 1 receptor blockers (ARBs) 18 (34.0)b
calcium channel blockers 13 (24.5)
diuretics 7 (13.2)
angiotensin-converting enzyme inhibitors 5 (9.4)
Anti-lipidemic agents
fenofibrate 2 (3.8)b
aData present mean ± SD
bData present the number and its percentage (%)
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decreased total cholesterol (TC), LDL-C, and sd-LDL-C
serum levels by 25.7, 39.4, and 41.7 %, respectively. Pita-
vastatin also significantly decreased sd LDL-C/LDL-C
levels by 4.5 % and serum CETP levels by 22.9 %, and sig-
nificantly increased ApoA-I levels by 3.5 %. In contrast,
no significant changes were observed in TG, HDL-C, or
HbA1c levels.
Relationships between clinical factors and LDL-C, sd-LDL-C,
or CETP levels at baseline
At baseline, LDL-C levels were negatively correlated with
age and ApoA-I levels (r = −0.343, P < 0.05 and r = −0.321,
P < 0.05, respectively) and positively associated with CETP
levels (r = 0.184, P = 0.21). A marginally positive associ-
ation was observed between LDL-C and CETP levels
(r = 0.284, P < 0.06) in patients with a CETP value of
less than 4.0 μg/mL (n = 47). sd LDL-C levels were
positively correlated with TG levels (r = 0.629, P < 0.01),
but not with CETP levels.
CETP levels were negatively correlated with age (r =
−0.347, P < 0.01), but were not associated with body
weight or abdominal girth. Furthermore, patients receiv-
ing pioglitazone (n = 10) had a significantly lower level of
CETP than those receiving no pioglitazone (n = 38; 2.12 ±
0.48 vs. 2.66 ± 0.58 μg/mL, P < 0.05) after adjustments
were made for age, while no other drugs had any influence
on CETP levels. Since pioglitazone use was a reducer of
CETP levels, it was included as an independent variable
when associations of CETP status with percent changes in
LDL-C and sdLDL-C levels were analyzed.
Relationship between clinical variables and percentage
changes in LDL-C
We analyzed relationships between the baseline levels of
clinical variables and percentage changes in LDL-C
levels to determine what clinical variables affected
pitavastatin-induced changes in LDL-C levels (Table 3).
Selected candidate determinants for changes in LDL-C
were shown in Table 3. Multiple regression analyses
identified TC as an independent negative determinant
and CETP as an independent positive determinant
(Table 3). When four patients receiving previous treat-
ment with mild statin were excluded, the same results
were obtained. CETP failed to be an independent pre-
dictor when the two patients with a CETP level of
4.9 μg/mL were included.
Relationships between percentage changes in clinical
variables and changes in LDL-C levels were then ana-
lyzed (Table 3). Selected candidate determinants for
changes in LDL-C were shown in Table 3. A multiple re-
gression analysis retained changes in body weight and
CETP as independent positive determinants, with the
standard partial correlation coefficient of the latter being
markedly stronger (Table 3). When the two patients with
a CETP level of 4.9 μg/mL were included or four pa-
tients with previous statin treatment were excluded, the
multiple regression analysis produced the same results.
Furthermore, percentage reductions in LDL-C levels
were significantly larger in the subgroup with sub-median
CETP levels at baseline (<2.6 μg/mL, n = 21) than in the
groups with supra-median CETP values (n = 23; Table 4).
Similar results were also found when the two patients with
a CETP level of 4.9 μg/mL were included.
Relationship between clinical variables and percentage
changes in sd LDL-C
We analyzed relationships between the baseline levels of
clinical variables and pitavastatin-induced changes in sd
LDL-C levels (Table 5). Selected candidate determinants
for percentage changes in sd LDL-C levels were shown
Table 2 Clinical data profile of pre- and post-pitavastatin treatment
Variables n baseline n Post-treatment Change (%) P value
Body weight (kg) 53 64.1 ± 15.4 52 64.4 ± 16.2 0.7 ± 2.4 0.052
HbAlc (%) 53 7.1 ± 0.80 53 7.2 ± 0.84 1.6 ± 7.6 0.13
eGFR (ml/min/m2) 52 75.4 ± 16.9 51 76.8 ± 16.5 4.2 ± 17.2 0.18
BUN (mg/dL) 52 14.7 ± 4.2 50 14.8 ± 3.9 −2.3 ± 23.8 0.49
Uric acid (mg/dL) 52 5.2 ± 1.4 51 4.9 ± 1.2 −4.7 ± 14.1 0.02
TC (mg/dL) 53 234.3 ± 28.9 48 173.0 ± 25.8 −25.7 ± 9.9 <0.01
TG (mg/dL) 53 146.7 ± 74.1 48 134.2 ± 87.0 −4.1 ± 55.3 0.61
HDL-C (mg/dL) 53 58.8 ± 14.8 49 58.7 ± 15.5 −0.6 ± 11.4 0.7
LDL-C (mg/dL) 53 152.1 ± 29.2 49 91.2 ± 25.4 −39.4 ± 13.6 <0.01
sd LDL-C (mg/dL) 53 52.0 ± 18.1 49 28.7 ± 10.4 −41.7 ± 18.0 <0.01
sd LDL-C/LDL-C (%) 53 33.9 ± 8.4 49 31.6 ± 7.3 −4.5 ± 15.6 0.047
ApoA-I (mg/dL) 53 142.9 ± 26.6 48 148.5 ± 26.7 3.5 ± 8.4 <0.01
CETP (μg/mL) 48 2.54 ± 0.60 46 1.98 ± 0.73 −22.9 ± 19.5 < 0.01
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Table 3 Linear regression analyses of baseline values and percent changes in clinical factors affecting the percent change in LDL-C
levels
Univariate Multivariate
n βa 95 % CIb p n βc 95 % CIb p
BMI (kg/m2) 46 0.17 −0.39 ~ 1.39 0.27d
Gender (Male = 1, Female = 2) 47 −0.13 −11.5 ~ 4.59 0.39
Age (year) 47 −0.24 −0.72 ~ 0.06 <0. 1 44 −0.07 −0.55 ~ 0.38 0.7
Body weight (kg) 47 0.3 0.02 ~ 0.52 0.04 44 0.07 −0.24 ~ 0.36 0.68
Abdominal girth (cm) 45 0.11 −0.28 ~ 0.59 0.47
HbA1c (%) 47 0.08 −3.57 ~ 6.38 0.57
Uric acid (mg/dL) 47 0.05 −2.3 ~ 3.26 0.74
TC (mg/dL) 47 −0.37 −0.29 ~ −0.04 0.011 44 -0.39 −0.30 ~ −0.05 0.009
LDL-C (mg/dL) 47 −0.21 −0.22 ~ 0.04 0.15e
TG (mg/dL) 47 −0.1 −0.07 ~ 0.04 0.5
HDL-C (mg/dL) 47 −0.32 −0.56 ~ −0.03 0.03 44 −0.16 −0.42 ~ 0.13 0.29
sd LDL-C (mg/dL) 47 −0.29 −0.43 ~ 0.01 0.04e
ApoA-I (mg/dL) 47 −0.28 −0.29 ~ 0.003 0.05f
CETP (μg/mL) 44 0.38 2.09 ~ 15.69 0.01 44 0.41 2.91 ~ 16.5 0.006
Pioglitazone use 47 −0.02 −12.1 ~ 10.63 0.9
Change in Body weight (%) 47 0.19 −0.57 ~ 2.66 0.2 43 0.36 0.44 ~ 3.64 0.01
Change in HbA1c (%) 47 −0.009 −0.56 ~ 0.52 0.95
Change in Uric acid (%) 47 0.14 −0.15 ~ 0.43 0.33
Change in TG (%) 46 0.22 −0.02 ~ 0.12 0.15 43 0.17 −0.02 ~ 0.10 0.2
Change in HDL-C (%) 47 −0.07 −0.47 ~ 0.29 0.64
Change in ApoA-I (%) 46 0.06 −0.48 ~ 0.71 0.71
Change in CETP (%) 44 0.44 0.12 ~ 0.52 0.003 43 0.57 0.21 ~ 0.60 0.0001
astandard regression coefficient
bconfidence interval
cstandard partial regression coefficient
dBMI was excluded from multivariate analysis, since colinearity between BMI and body weight was found
eLDL-C and sd LDL-C were excluded from multivariate analysis, since colinearity among TC, LDL-C and sd LDL-C was found
fApoA-I was excluded from multivariate analysis, since colinearity between HDL-C and ApoA-I was found
Table 4 Comparison of lipid data between patients with below- and abovemedian CETP levels
Patients with CETP levels below the median
(<2.6μg/mL; n = 21 )
Patients with CETP levels above the median
(≧ 2.6 μg/mL; n = 23 )
p
Baseline CETP (p,g/mL) 2.12 ± 0.3 3.01 ± 0.44 <0.01
Post-treatment CETP (p,g/mL) 1.48 ± 0.36 2.44 ± 0.71 <0.01
Change in CETP (%) −28.9 ± 20.3 −19.2 ± 17.0 0.09
Baseline LDL-C (mg/dL) 143.5 ± 234.1 157.0 ± 34.9 0.14
Post-treatment LDL-C (mg/dL) 75.1 ± 15.2 103.6 ± 26.3 <0.01
Change in LDL-C (%) −46.4 ± 11.2 −33.1 ± 13.1 <0.01
Baseline sd LDL-C (mg/dL) 51.8 ± 16.3 51.7 ± 20.6 0.98
Post-treatment sd LDL-C (mg/dL) 23.9 ± 6.5 32.7 ± 12.1 <0.01
Change in LDL-C (%) −49.6 ± 13.7 −33.5 ± 19.2 <0.01
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in Table 5. Multiple regression analyses retained TC as
an independent negative determinant and CETP as an
independent positive determinant (Table 5). Exclusion of
four patients with previous statin treatment produced
the same results. When the two patients with a CETP
level of 4.9 μg/mL were included, CETP failed to be an
independent determinant.
Relationships between percentage changes in clinical
variables and changes in sd LDL-C were then analyzed
(Table 5). Selected candidate determinants for the changes
induced in sd LDL-C were shown in Table 5. A multiple
regression analysis retained changes in body weight, and
CETP as independent positive determinants, with the
standard partial correlation coefficient of the last being
the strongest (Table 5). When the two patients with a
CETP level of 4.9 μg/mL were included or four patients
with previous statin treatment were excluded, the multiple
regression analysis produced the same results.
Furthermore, percentage reductions in sd LDL-C
levels were significantly greater in the subgroup with
sub-median CETP levels than in the subgroup with
supra-median CETP levels (Table 4). Similar results were
also observed when the two patients with a CETP level
of 4.9 μg/mL were included.
Effects of pitavastatin and T0901317 on the expression of
lipid metabolism-related genes in HepG2 cells
First, we examined the cytotoxic effects of pioglitazone
and T0901317 on HepG2 cells by measuring LDH levels
in the supernatants. Pitavastatin did not significantly in-
crease the levels of LDH in the supernatants at 1, 2.5 or
5 μM (109 ± 22 %, 103 ± 15 %, and 110 ± 17 %, respect-
ively). T0901317 did not significantly increase the LDH
levels at 0.1, 1 or 10 μM (94 ± 4 %, 97 ± 25 %, and 101 ±
1 % and 92 ± 11 %, respectively). Therefore, pitavastatin
Table 5 Linear regression analyses of baseline values and percent changes in clinical factors affecting the percent change in sd
LDL-C levels
Univariate Multivariate
n βa 95 % CIb p n βc 95 % CIb p
BMI (kg/m2) 46 0.04 −1.07 ~ 1.37 0.8
Gender (Male = 1, Female = 2) 47 −0.18 −17.18 ~ 4.34 0.24 44 −0.11 −16.4 ~ 8.13 0.5
Age (year) 47 −0.1 −0.72 ~ 0.36 0.5
Body weight (kg) 47 0.18 −0.13 ~ 0.56 0.22 44 0.03 −0.38 ~ 0.44 0.88
Abdominal girth (cm) 45 0.08 −0.44 ~ 0.74 0.61
HbA1c (%) 47 0.2 −2.07 ~ 11.1 0.17 44 0.19 −2.54 ~ 11.1 0.21
Uric acid (mg/dL) 47 0.1 −2.45 ~ 5.02 0.49
TC (mg/dL) 47 −0.42 −0.41 ~ −0.09 0.004 44 −0.43 −0.46 ~ −0.06 0.01
LDL-C (mg/dL) 47 -0.29 −0.34 ~ −0.002 0.05d
TG (mg/dL) 47 −0.18 −0.12 ~ 0.03 0.23 44 −0.04 −0.09 ~ 0.07 0.8
HDL-C (mg/dL) 47 −0.24 −0.66 ~ 0.06 0.11 44 −0.02 −0.45 ~ 0.41 0.92
sd LDL-C (mg/dL) 47 −0.42 −0.68 ~ −0.14 0.004d
ApoA-I (mg/dL) 47 −0.22 −0.36 ~ 0.05 0.14e
CETP (μg/mL) 44 0.29 −0.15 ~ 18.67 0.054 44 0.32 0.27 ~ 20.2 0.04
Pioglitazone use 47 0.02 −14.13 ~ 16.5 0.88
Change in Body weight (%) 47 0.35 0.05 ~ 4.29 0.02 43 0.43 1.24 ~ 5.26 0.002
Change in HbA1c (%) 47 −0.13 −1.2 ~ 0.23 0.37
Change in Uric acid (%) 47 0.12 −0.22 ~ 0.56 0.41
Change in TG (%) 46 0.32 0.01 ~ 0.2 0.03 43 0.26 −0.0001 ~ 0.16 0.05
Change in HDL-C (%) 47 0.011 −0.42 ~ 0.61 0.94
Change in ApoA-I (%) 46 0.11 −0.31 ~ 1.28 0.48
Change in CETP (%) 44 0.32 0.03 ~ 0.6 0.03 43 0.46 0.19 ~ 0.66 0.001
astandard regression coefficient
bconfidence interval
cstandard partial regression coefficient
dLDL-C and sd LDL-C were excluded from multivariate analysis, since colinearity among TC, LDL-C and sd LDL-C was found
eApoA-I was excluded from multivariate analysis, since colinearity between HDL-C and ApoA-I was found
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and T0901317 are considered to have no cytotoxic ef-
fects at the above concentrations.
Pitavastatin (5 μM) decreased CETP and sterol regula-
tory element-binding protein-1c (SREBP-1c) mRNA
levels by 21 and 30 % at 5 μM, respectively (Fig. 1), and
increased ApoA-I mRNA levels by 29 % (Fig. 1). After
pitavastatin treatment (1 and 5 μM), mRNA levels of
LXR-α and LXR-β did not change significantly (97 ± 6 %
and 107 ± 10 %, and 101 ± 1 % and 102 ± 9 %, respect-
ively). T0901317, a specific agonist of LXR-α and LXR-β,
significantly elevated CETP mRNA levels by 1.8-fold at
0.1 μM, by 2.2-fold at 0.5 μM, by 2.2-fold at 1.0 μM, and
by 2.3-fold at 10 μM and SREBP-1c mRNA levels by 1.8-
fold at 3 nM, by 2.7-fold at 10 nM, by 3.7-fold at 100
nM, by 4.2-fold at 0.5 μM, by 4.0-fold at 1.0 μM, and by
4.0-fold at 10 μM, reaching a plateau of 2.2- and 4.2-fold
at 0.5 μM (Fig. 2a), respectively, while it decreased
ApoA-I mRNA levels by 11 and 61 % at 1 and 10 μM,
respectively (Fig. 2b). T0901317 also reversed the
pitavastatin-induced decline in the gene expression
levels of CETP and SREBP-1c (Fig. 1). The reduction ob-
served in the expression of SREBP-1c was completely
abolished by T0901317, even at a concentration as low
as 3 nM (Fig. 1) as well as 0.5 μM. Furthermore, the si-
lencing of LXR-α and LXR–β markedly inhibited the
T0901317-induced expression of CETP mRNA (Fig. 3).
These results confirmed that CETP and SREBP-1c were
Fig. 1 Pitavastatin decreased CETP and SREBP-1c mRNA levels, and
increased ApoA-I mRNA levels in HepG2 cells, and T0901317
abolished the decreasing effects. HepG2 cells grown to semi-
confluence were treated with DMEM containing no pitavastatin or
T0901317 (control), 5 μM pitavastatin alone, or 5 μM pitavastatin plus
T0901317 (3 or 500 nM) for 24 h. Results were the mean ± SD of
three independent experiments in duplicate or triplicate (n = 8-9).
*P < 0.05 and **P < 0.01 significantly different from cells under the
indicated conditions, according to ANOVA with Scheffé’s post hoc
test. Footnote: Concentrations used of T0901317 were different
(500nM for CETP and 3 nM for SREBP-1c) in order to show clearly
significant differences in CETP and SREBP-1c expression among
three groups
Fig. 2 T0901317 increased CETP and SREBP-1c mRNA levels, and
decreased ApoA-I mRNA levels in HepG2 cells. HepG2 cells grown to
semi-confluence were treated with DMEM containing 0 (control), 1,
or 10 μM T0901317 for 24 h. TaqMan real-time PCR was performed
for CETP (a), SREBP-1c (a), ApoA-I (b), and β-actin. Results were the
mean ± SD of three to five independent experiments in triplicate
(n = 9–15). *P < 0.05 and **P < 0.01 significantly different from cells
under the indicated conditions, according to an unpaired t-test for
Fig. 2a and ANOVA with Scheffé’s post hoc test for Fig. 2b Footnote:
The inhibitory effect of T0901317 on ApoA-I expression was relatively
weak and thus the concentrations of 1 and 10 μM were used in
order to show a considerable reduction of ApoA-I expression
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positive target genes of LXR in HepG2 cells, as reported
previously [6, 7].
Discussion
Sd LDL has been shown to be more atherogenic than LDL
due to its longer half-time, greater penetrance into arterial
walls, and susceptibility to oxidative stress [9]. Several clin-
ical studies reported that smaller LDL particles were associ-
ated with the incidence of coronary artery disease [10–12].
Dyslipidemia in type 2 diabetes mellitus is characterized by
high TG levels, low HDL-C levels, and high sd LDL levels
[13]. In type 2 diabetes mellitus, free fatty acids, which are
released from adipocytes due to insulin resistance, are
taken up by the liver. The resulting hepatic accumulation
of free fatty acids increases TG-enriched VLDL production
and readily gives rise to the formation of TG-rich LDL.
The hepatic lipase-processing of TG-rich LDL finally
produces small dense LDL particles. These mechanisms
account for the increase frequently observed in sd LDL
levels in type 2 diabetes mellitus [13, 14]. The greater
atherogenic feature of sd LDL than LDL appears to be of
importance when evaluating the reducing effects of statin
treatments on sd LDL-C as well as LDL-C levels in hyper-
cholesterolemic patients with type 2 diabetes mellitus.
In the present study, pitavastatin produced a marked
reduction not only in LDL-C, but also sd LDL-C levels.
This result supported earlier clinical studies in which
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Fig. 3 LXR silencing inhibited T0901317-stimulated CETP expression in HepG2 cells. HepG2 cells (30–40 % confluence) were transfected with
negative control siRNA or siRNA against LXR-α (a and b) or LXR-β (c and d) (25nM each). After a 48-h incubation, HepG2 cells that had been
refreshed with DMEM were treated with or without T0901317 (500 nM) for an additional 24 h (b and d). Protein amounts of LXR-α (a), LXR-β (c),
and β-actin in the cell lysates were determined by immunoblot analyses. Results were the mean ± SD of an independent experiment in triplicate
or quadruplicate (n = 3-4). NS, not significant; *P < 0.05 and **P < 0.01 significantly different from cells under the indicated conditions, according
to an unpaired t-test for Fig. 3a and c and ANOVA with Scheffé’s post hoc test for Fig. 3b and d
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mellitus [15] or familial hypercholesterolemia [16]. Both
LDL reductions were largely explained by the increased
expression of LDL receptors due to the decreased syn-
thesis of intrahepatic cholesterol. Sd LDL particles have
been shown to have a weaker affinity for the LDL recep-
tor than large buoyant LDL [18], while the induction of
the LDL receptor by statin reportedly stimulates the up-
take of all LDL particles, irrespective of their size [15].
Thus, the pitavastatin-induced expression of LDL recep-
tors may have enhanced the hepatic uptake of sd LDL in
addition to LDL, which subsequently led to reductions
in both LDL-C and sd LDL-C levels.
One of the most important results of the present study
was the correlation between serum CETP levels and the
lipid-reducing effects of pitavastatin. Serum CETP levels
prior to the pitavastatin treatment were positively linked
to pitavastatin-induced changes in LDL-C and sd LDL-C
levels. Lower basal CETP levels induced greater negative
changes in lipid levels, while higher CETP levels caused
smaller negative changes. In multivariate analyses in-
cluding baseline TC and LDL-C levels as independent
factors, basal CETP levels were independently and posi-
tively associated with changes in LDL-C or sd LDL-C
levels. Moreover, pitavastatin decreased serum CETP
levels, and these negative percentage changes were
strongly and positively associated with the negative per-
centage changes observed in LDL-C and sd LDL-C.
These results suggested that the CETP status during the
pitavastatin treatment was markedly associated with the
pharmacological effects observed.
The main limitation of our study was that postprandial
lipids were measured. Several earlier studies of postprandial
lipid changes in healthy subjects showed that levels of LDL-
C and sdLDL-C significantly decreased by about 7–9 % at
2–6 h after a meal [19–21]. In diabetic patients, post-
prandial reduction of LDL-C and sdLDL-C was shown to
be about 10 % [22]. However, lipid data variation during
2–6 h after a meal appeared to be much smaller (about
5 %) even in diabetic patients as well as healthy subjects
[19–22]. Considering these findings, it seems probably that
measurement of postprandial lipid had some degree of
influence on the results obtained in our study. It might have
affected the measured values positively or negatively de-
pending on the time points of blood collection after a meal.
CETP is a 74-kDa glycoprotein that is synthesized in
liver and adipose tissues and subsequently secreted into
the bloodstream [1]. Serum CETP levels are known to
be up-regulated by a high fat diet for several days and
high LDL-C levels, and down-regulated by statin treat-
ments [1, 4, 17, 23]. The expression of CETP was shown
to be induced by LXR [5, 6], which was clearly con-
firmed in our present study with LXR silencing in
HepG2 cells (Fig. 3). Since endogenous agonists of LXR
are oxysterols, a cholesterol derivative [7], hepatic
cholesterol content may be positively related to the ex-
pression of CETP, as previously discussed [8]. Atorva-
statin, a strong statin, was shown to decrease the
expression of LXR-α in macrophages [24]. Pitavastatin
repressed LXR activation in a rat hepatoma cell line
[25], which was indirectly supported by our result in
which the activation of LXR by T0901317 antagonized
the pitavastatin-induced reduction in CETP levels in
HepG2 cells (Fig. 1). Statin-induced reductions in oxy-
sterol, the endogenous activator of LXR, may lead to a
partial reduction in LXR activity [7], and consequently
to a reduction in its target genes, CETP and SREBP-1c.
These findings implicate the intrahepatic reduction in
the mass or activity of LXR in the statin-mediated de-
crease in serum CETP levels reported in ours and sev-
eral previous studies [1, 4, 17]. Furthermore, elevated
CETP levels in the serum of CETP transgenic mice led
not only to an increase in hepatic cholesterol content,
but also to the reduced expression of the LDL receptor
[26]. Collectively, elevated CETP levels at baseline may
reflect an increased hepatic cholesterol content, which
may weaken the statin-induced up-regulation of LDL re-
ceptor expression, and ultimately attenuate cholesterol-
reducing effects. This may explain our result in which
lower baseline CETP levels were associated with a
greater negative change in LDL-C and sd LDL-C levels.
Statin-modulated LXR expression may be tissue-
specific and different among type of statins. Atrovastatin
increased expression of LXR-α and LXR-β in HepG2
cells [27] but decreased LXR-α expression in macro-
phages as mentioned above [24], while in our study pita-
vastatin had no influence on LXR expression even at
5 μM. Simvastatin increased LXR-α expression in per-
ipheral blood mononuclear cells from diabetic patients
with hyperlipidemia [28], but had no effect on the ex-
pression in those from non-diabetic hyperlipidemic pa-
tients [27]. Therefore, the reduction of LXR expression
by statin may occur only under restrictive conditions.
Statin-induced reduction of LXR activity may be due
largely to reduction of intrahepatic oxy-sterols, endogen-
ous LXR activators.
Pitavastain-induced reduction of SREBP-1c activity is
presumed by ApoA-I induction found in our study. Since
ApoA-I was previously shown to be up-regulated by liver
receptor H-1 (LRH-1) [29], the function of which is
suppressed by SREBP-1c [30], pitavastatin may reduce
SREBP-1c activity and subsequently enhance LRH-1 func-
tion, possibly leading to ApoA-I induction (Fig. 1).
CETP enhances the exchange of CE in LDL as well as
HDL for TG in VLDL [2]. This action causes the accumu-
lation of TG in LDL particles as well as HDL particles. In
co-operation with CETP, hepatic TG lipase has been
shown to induce reductions in the size of LDL via the
lipolysis of TG and increases in sd LDL-C levels [2, 13]. In
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the present study, a positive correlation was not observed
between CETP and LDL-C or sd LDL-C at baseline. This
may have been due to individual differences in sd LDL-C
modifiers such as TG levels themselves and hepatic TG
lipase activity according to gene polymorphisms [31, 32].
In contrast, an independent positive association was
observed between percentage changes in CETP and those
in sd LDL-C because percentage changes in lipids repre-
sented the standardized effects of statins in each individ-
ual. Furthermore, the pitavastatin-induced suppression of
cholesterol synthesis in the liver may be a common path-
way to the induction of LDL receptor expression and the
reduction in CETP expression. Additionally, pitavastatin-
induced reductions in CETP may decrease the rate of sd
LDL formation.
Finally, several limitations exist in the present study.
Our results were obtained from a small-scale and ex-
ploratory study consisting of approximately 50 subjects.
Statistical power of paired t-test calculated by a post-hoc
method using the data from our study was over 0.9 for
pitavastatin-induced reductions in CETP. However, we
were not able to calculate the adequate sample size
based on reported data, since there are no earlier studies
to investigate the influence of CETP status on the lipid-
reducing effects of strong stains, similar to ours. Fur-
thermore, it is considered preferable to measure fasting
lipid levels and examine HDL particle composition.
Therefore, a large-scale study with a more detailed
examination of fasting lipid profiles is required to com-
pletely define the relationship between the CETP status
and lipid-lowering effects of statins.
Conclusions
The baseline CETP level, a possible surrogate for hepatic
cholesterol accumulation, was an independent positive
determinant of pitavastatin-induced changes in LDL-C
and sd LDL-C levels in hypercholesterolemic patients
with type 2 diabetes mellitus. Concurrent and compar-
able reductions in serum CETP and LDL-C levels
suggest that pitavastatin may decrease LXR activity as
well as cholesterol synthesis in the liver.
Methods
Subjects
The study protocol and informed consent document
were reviewed and approved by the Ethics Committees
of 6 Hospitals (University of Fukui Hospital, its two
affiliated facilities; Fukui Chuo Clinic and Yasukawa
Hospital, Tanaka Hospital, Fukui-ken Saiseikai Hospital,
and Fukui Prefectural Hospital). This study was regis-
tered in UMIN-CTR (ID: UMIN000019020). After being
fully informed regarding all aspects of their participation
in this study, informed written consent was obtained
from all the outpatients. The inclusion criteria were as
follows: (1) all subjects had type 2 diabetes mellitus and
hypercholesterolemia (LDL-C levels of 120 mg/dL or
more, or TC levels of 220 mg/dL or more, at baseline);
(2) all subjects were aged between 20 and 80 years; (3)
the diabetic condition of all subjects was stable in that
the last 2 values of HbA1c were less than 8.4 % (NGSP)
with its percentage change being within 10 %. Fifty-three
patients who met the inclusion criteria were enrolled in
this study. Patients were treated with 2 mg of pitavasta-
tin daily for 3 months. For four patients receiving mild
statin (pravastatin, n = 3; fluvastatin, n = 1), pitavastatin
was prescribed in exchange for the mild stain with no
washout period. Two patients on fenofibrate were ex-
cluded from statistical analyses for investigating the as-
sociations of CETP status with lipid-reducing effects of
pitavastatin. Dietary and exercise instructions did not
change in any patient during the 3-month treatment,
and medications that are known to influence lipid me-
tabolism were neither added nor withdrawn. Blood sam-
ples were obtained in the post-absorptive state before
and after the pitavastatin treatment, and serum was
stored at -80 °C until later analysis.
In order to examine postprandial changes in serum
CETP levels, blood samples were obtained before and
2 h after breakfast from ten patients with type 2 diabetes
mellitus who were admitted to Fukui-ken Saiseikai
Hospital and then provided written informed consents,
and serum was stored at -80 °C until later analysis.
Biochemical assays
TC, TG, creatinine (Cr), blood urea nitrogen, and uric
acid serum levels and supernatant LDH levels were
measured using a standard enzymatic method. The esti-
mated glomerular filtration rate (eGFR) was calculated
from serum Cr levels using the new 3-variable Japanese
equation [33]. LDL-C and HDL-C serum levels were
measured by direct and chemical measurements using
commercial kits (Cholestest-LDL and Cholestest-N
HDL, respectively; Sekisui Medical, Tokyo, Japan). Sd
LDL-C serum levels were measured using a commer-
cially available kit (sdLDL-C “Seiken”, Denka Seiken Co.
Ltd., Tokyo, Japan), the details and validation of which
were described previously [34]. HbA1c levels were
measured by high-performance liquid chromatography.
ApoA-I levels were measured by an immunochemistry
system using nephelometry (APOA-I AUTO N “Dai-
ichi”, Sekisui Medical). CETP concentrations in the
serum were measured using an enzyme-linked immuno-
sorbent assay with monoclonal antibodies (BML, Sai-
tama, Japan). We measured the postprandial serum
levels of lipids and proteins for the following reasons: (1)
it was difficult to collect fasting blood samples from all
patients because approximately 50 % of patients typically
underwent a medical examination in the afternoon in
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the outpatient clinics of the 6 hospitals; (2) a previous
study reported that total cholesterol levels were un-
changed and HDL-C levels did not change significantly
(less than 10 %) in healthy subjects after a meal [19]; (3)
we previously reported that no significant difference was
observed in serum CETP levels during fasting and 2 h
after a meal in healthy subjects [35]; (4) in our pilot
study, we observed no significant difference in serum
CETP levels before and 2 h after breakfast (2.2 ± 0.70 vs.
2.1 ± 0.61 μg/mL) in patients with type 2 diabetes melli-
tus (n = 10).
Evaluation of effects of pitavastatin on the expression of
genes related to lipid metabolism in the HepG2 cell line
HepG2 cells, a human hepatoma cell line (JCRB1054),
were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) (Life Technologies Corp., Carlsbad, CA USA)
supplemented with high glucose (450 mM), 10 % fetal
bovine serum (FBS; Life Technologies Corp.), and 1 %
penicillin/streptomycin (Life Technologies Corp.) in a
humidified atmosphere containing 5 % CO2 and 95 % air
at 37 °C. The cells were seeded on 12-well plates at a
density of 3 × 105 cells/well in DMEM supplemented
with high glucose, 10 % FBS, and antibiotics. Cells grown
to semi-confluence were treated for 24 h with DMEM
containing T0901317 (Cayman Chemical Co., Michigan,
IN, USA; 3 nM to 10 μM), pitavastatin (Kowa Co. Ltd.,
Nagoya, Japan; 1 to 10 μM), or T0901317 plus pitavasta-
tin. Total RNA was extracted from the HepG2 cells thus
treated using a commercial instrument (MFX-2100,
Toyobo, Co., Ltd. Osaka, Japan) and commercially
available kit (MagExtractor –RNA-, Toyobo, Co., Ltd.).
cDNA was synthesized with a High Capacity cDNA
Archive kit (Life Technologies Corp.) according to the
supplied protocol. TaqMan real-time RT–PCR was per-
formed with a TaqMan ABI 7000 Sequence Detection
System (Life Technologies Corp.) using TaqMan Universal
PCR Master Mix (Roche Diagnostics K.K., Tokyo, Japan).
Unlabeled specific primers and TaqMan MGB probes (6-
FAM dye-labelled) from Applied Biosystems were used to
detect human CETP (assay ID: Hs00163942_m1), human
sterol-regulatory element-binding protein-1c (SREBP-1c;
assay ID: Hs01088691_m1), human LXR-α (assay ID:
Hs00172885_m1), human LXR-β (assay ID: Hs0017
3195_m1), and human ApoA-I (assay ID: Hs0098
5000_m1). A TaqMan human β-actin MGB (VIC dye-
labeled) control reagent kit (Applied Biosystems, accession
no: NM_001101) was used to detect human β-actin. The
CETP, SREBP-1c, LXR-α, LXR–β, ApoA-I, and β-actin
cDNA templates were quantified separately using stand-
ard curves produced via the serial dilution of standard
cDNA. The threshold cycle of each sample was converted
to a standard cDNA dilution value (arbitrary units). The
cDNA contents of CETP, SREBP-1c, LXR-α, LXR–β, and
ApoA-I for each sample were normalized to the level of β-
actin, a housekeeping gene, for quantitative analyses. The
averaged mRNA amounts of each gene for control cells
were set at 1.0.
Transfection of small interfering RNA against LXR-α or -β
Small interfering RNAs (siRNA) against LXR-α or -β,
and control siRNA (a non-targeting siRNA) were pur-
chased from Thermo Scientific Dharmacon (Lafayette,
CO, USA). HepG2 cells (30–40 % confluence) were
transfected with negative control siRNA or siRNA
against LXR-α or -β, at a final concentration of 25 nmol/
L using the Lipofectamine RNAiMAX transfection re-
agent (Invitrogen Corp, Carlsbad, CA, USA), according
to the manufacturer’s instructions. After a 48-h incuba-
tion, HepG2 cells that had been refreshed with DMEM
were treated with or without T0901317 (500 nM) for an
additional 24 h and LXR and CETP mRNA expression
levels were then analyzed.
Immunoblot analysis
HepG2 cells were lysed in RIPA buffer containing phos-
phatase inhibitors (SIGMA-Aldrich, St Louis, MO,
USA). Ten micrograms of protein was separated on an
8 % SDS-polyacrylamide gel and then electrophoretically
transferred to nitrocellulose membranes (Trans-Blot SD;
BioRad, Hercules, CA, USA). The membranes were
blocked with Blocking One (Nacalai Tesque, Kyoto,
Japan) in Tris-buffered saline (pH 8.0) containing 0.05 %
Tween-20 at 37 °C for 1 h and then incubated with a
mouse monoclonal antibody against human LXR-α
(Cosmo Bio.;Co., Ltd., Tokyo, Japan; 1:200 dilution) or
rabbit polyclonal antibody against human LXR-β
(SIGMA-Aldrich; 1:2000 dilution) or against human β-
actin (Abcam, Cambridge, UK) for 1 h at room
temperature. The membranes were then incubated with
secondary horseradish peroxidase-conjugated secondary
anti-mouse or anti-rabbit antibodies (Dako, Glostrup,
Denmark; 1:1000 dilution) at room temperature for 1 h.
The secondary antibodies were visualized using the ECL
detection system from Thermo Fisher Scientific (Pitts-
burg, PA, USA). The signal intensities of specific bands
were quantified with a densitometer (ImageQuant TL,
GE Healthcare UK Ltd, Buckinghamshire, UK).
Statistical analysis
Continuous variables were expressed as the mean ± SD.
The Kolmogorov-Smirnov test proved that all continu-
ous variables fit a normal distribution. Since the refer-
ence range of serum CETP levels was not formally
defined, several outliers (4.9 μg/mL or more) were ascer-
tained by the Smirnov-Grubbs test and omitted from
statistical analyses. Differences in continuous variables
between pre- and post-treatment were assessed by the
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paired t-test. Differences in continuous variables be-
tween two groups and among three groups were
assessed by the Student’s t-test and ANOVA with
Scheffé’s post-hoc test. The relationship between clinical
variables and LDL-C or sd LDL-C levels was examined
by Pearson’s analysis or a univariate regression analysis.
A p value of <0.3 was used as a criteria for selecting a
candidate determinant for multivariate regression ana-
lysis. A multiple linear regression analysis was performed
to identify the independent determinants for LDL –C or
sd LDL-C at baseline and their percentage changes.
When co-linearity was detected among independent var-
iables (correlation coefficient (r) >0.7), that with the
strongest univariate correlation with a dependent vari-
able was selected for the multivariate analysis. When in-
vestigating correlations between percentage changes in
clinical variables and those in LDL-C or sd LDL-C
levels, changes in TC and sd LDL-C or LDL-C, respect-
ively, were excluded from independent variables because
they were direct results of the change in LDL-C or sd
LDL-C levels. A p value of <0.05 (two-tailed tests) was
considered significant. All statistical analyses were per-
formed using the JMP system version 5.1.
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